Comments
Cipla has acquired the brand name and trademark rights of Vysov (Vildagliptin + Metformin) of the anti-diabetic drug Vildagliptin for the Indian market.
The company has been co-marketing Vildagliptin in agreement with Novartis and has witnessed strong uptake for the product in India for the last couple of years. The current market size of Vildagliptin in India is ₹818 crore, as per IQVIA MAT November 2019. However, Cipla did not disclose the cost of acquisition.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.